Brokerages Expect Ascendis Pharma A/S (ASND) Will Announce Quarterly Sales of $660,000.00

Analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will announce $660,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Ascendis Pharma A/S’s earnings. The highest sales estimate is $1.74 million and the lowest is $20,000.00. Ascendis Pharma A/S reported sales of $30,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 2,100%. The firm is scheduled to announce its next earnings results on Wednesday, May 29th.

On average, analysts expect that Ascendis Pharma A/S will report full year sales of $34.03 million for the current financial year, with estimates ranging from $90,000.00 to $128.00 million. For the next fiscal year, analysts forecast that the company will report sales of $29.56 million, with estimates ranging from $90,000.00 to $114.00 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.30. Ascendis Pharma A/S had a negative net margin of 1,275.08% and a negative return on equity of 40.86%. The business had revenue of $12.00 million during the quarter.

A number of research analysts have issued reports on the stock. Canaccord Genuity upped their price target on shares of Ascendis Pharma A/S from $132.00 to $133.00 and gave the company a “buy” rating in a research note on Friday, April 5th. BidaskClub lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Friday. Wedbush restated a “buy” rating and set a $219.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, April 8th. Cantor Fitzgerald assumed coverage on shares of Ascendis Pharma A/S in a research note on Wednesday, January 23rd. They set an “overweight” rating and a $102.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Ascendis Pharma A/S presently has a consensus rating of “Buy” and an average price target of $135.56.

Ascendis Pharma A/S stock traded up $0.64 during mid-day trading on Monday, reaching $107.75. 175,041 shares of the company traded hands, compared to its average volume of 375,257. Ascendis Pharma A/S has a fifty-two week low of $53.21 and a fifty-two week high of $131.76. The firm has a market capitalization of $4.53 billion, a price-to-earnings ratio of -28.81 and a beta of 1.01.

Several hedge funds have recently added to or reduced their stakes in ASND. Putnam Investments LLC purchased a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at $11,653,000. Bank of New York Mellon Corp purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at $7,732,000. Westpac Banking Corp purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at $5,461,000. New York State Common Retirement Fund boosted its holdings in shares of Ascendis Pharma A/S by 44.4% in the 4th quarter. New York State Common Retirement Fund now owns 233,049 shares of the biotechnology company’s stock valued at $14,601,000 after acquiring an additional 71,656 shares during the last quarter. Finally, Marshall Wace North America L.P. boosted its holdings in shares of Ascendis Pharma A/S by 9.9% in the 3rd quarter. Marshall Wace North America L.P. now owns 703,087 shares of the biotechnology company’s stock valued at $49,821,000 after acquiring an additional 63,540 shares during the last quarter. 95.46% of the stock is currently owned by institutional investors and hedge funds.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Article: Investing strategies using the yield curve

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.